Latham & Watkins Represents Lead Investor in Alterome Therapeutics’ US$132 Million Series B Financing

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, has announced the closing of a US$132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. The financing was led by Goldman Sachs Alternatives, with participation by other existing and new investors.

Latham & Watkins LLP advised Goldman Sachs in the offering with an Emerging Companies & Growth deal team led by Bay Area partner Saad Khanani, with associates Omar Ammash and Kayleigh Kuyon. Advice was also provided on FDA Regulatory matters by Washington, D.C. partner Ben Haas; on IP matters by Bay Area partner Judith Hasko, with associate Billy Wu; and on tax matters by Bay Area partner Grace Lee.